Ascelia Pharma AB (publ) (ACE.ST)
SEK 2.74
(1.67%)
SEK 2.74
(1.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -108.55 Million SEK | 16.31% |
| 2022 | -132.06 Million SEK | -2.83% |
| 2021 | -128.41 Million SEK | -28.9% |
| 2020 | -98.9 Million SEK | -173.76% |
| 2019 | -39.93 Million SEK | 2.23% |
| 2018 | -37.51 Million SEK | -51.75% |
| 2017 | -71 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -16.05 Million SEK | -29.37% |
| 2024 Q2 | -10.99 Million SEK | 31.5% |
| 2023 Q1 | -36.4 Million SEK | 31.65% |
| 2023 Q4 | -12.41 Million SEK | 40.27% |
| 2023 FY | - SEK | 17.04% |
| 2023 Q2 | -40.01 Million SEK | -9.94% |
| 2023 Q3 | -20.77 Million SEK | 48.08% |
| 2022 Q2 | -23.78 Million SEK | 20.74% |
| 2022 Q1 | -30.01 Million SEK | 21.11% |
| 2022 FY | - SEK | -2.83% |
| 2022 Q3 | -26.04 Million SEK | -9.5% |
| 2022 Q4 | -53.25 Million SEK | -104.47% |
| 2021 Q1 | -29.29 Million SEK | 36.13% |
| 2021 FY | - SEK | -28.9% |
| 2021 Q2 | -32.31 Million SEK | -10.29% |
| 2021 Q3 | -29.79 Million SEK | 7.81% |
| 2021 Q4 | -38.04 Million SEK | -27.71% |
| 2020 FY | - SEK | -173.76% |
| 2020 Q2 | -26.2 Million SEK | -56.15% |
| 2020 Q4 | -45.87 Million SEK | -321.45% |
| 2020 Q3 | -10.88 Million SEK | 58.46% |
| 2020 Q1 | -16.77 Million SEK | 25.73% |
| 2019 Q2 | -14.41 Million SEK | -23.12% |
| 2019 Q1 | -11.7 Million SEK | -61.64% |
| 2019 FY | - SEK | 2.23% |
| 2019 Q4 | -22.59 Million SEK | -77.59% |
| 2019 Q3 | -12.72 Million SEK | 11.75% |
| 2018 Q1 | -4.4 Million SEK | 52.69% |
| 2018 FY | - SEK | -51.75% |
| 2018 Q2 | -8.18 Million SEK | -85.83% |
| 2018 Q3 | -3.94 Million SEK | 51.76% |
| 2018 Q4 | -7.24 Million SEK | -83.53% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | -9.3 Million SEK | -88738.1% |
| 2017 Q3 | 10.5 Thousand SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 70.485% |
| AcouSort AB (publ) | -16.7 Million SEK | -549.931% |
| Active Biotech AB (publ) | -43.88 Million SEK | -147.358% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 258577.583% |
| Amniotics AB (publ) | -27.14 Million SEK | -299.948% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -663.579% |
| BioArctic AB (publ) | 275.38 Million SEK | 139.42% |
| Camurus AB (publ) | 562.54 Million SEK | 119.298% |
| Cantargia AB (publ) | -284.31 Million SEK | 61.818% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -454.461% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -535.418% |
| Genovis AB (publ.) | 64.57 Million SEK | 268.119% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 5.525% |
| Mendus AB (publ) | -97.84 Million SEK | -10.948% |
| Kancera AB (publ) | -61.88 Million SEK | -75.408% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -305.324% |
| LIDDS AB (publ) | -39.67 Million SEK | -173.653% |
| Lipum AB (publ) | -37.11 Million SEK | -192.459% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -796.877% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 445.682% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 5428000.0% |
| NextCell Pharma AB | -40.98 Million SEK | -164.872% |
| OncoZenge AB (publ) | 7.26 Million SEK | 1594.055% |
| Saniona AB (publ) | -69.69 Million SEK | -55.762% |
| Simris Alg AB (publ) | -22.36 Million SEK | -385.436% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 65.805% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 61.509% |
| Xintela AB (publ) | -53.47 Million SEK | -103.022% |
| Ziccum AB (publ) | -20.34 Million SEK | -433.664% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -193.21% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 36.073% |
| CombiGene AB (publ) | -35.33 Million SEK | -207.216% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 22.927% |
| Intervacc AB (publ) | -68.98 Million SEK | -57.376% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 54.313% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -5119.135% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -708.264% |
| Corline Biomedical AB | -1.69 Million SEK | -6319.752% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 37.367% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -98.077% |
| Aptahem AB (publ) | -10 Million SEK | -984.579% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 1039.977% |
| Fluicell AB (publ) | -25.91 Million SEK | -318.916% |
| Biovica International AB (publ) | -119.5 Million SEK | 9.161% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -157.1% |
| Abliva AB (publ) | -93.6 Million SEK | -15.971% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 65.98% |
| 2cureX AB (publ) | -35.13 Million SEK | -208.965% |
| I-Tech AB | 30.34 Million SEK | 457.746% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 84.808% |
| Cyxone AB (publ) | -20.41 Million SEK | -431.782% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -5.959% |
| Biosergen AB | 228 Thousand SEK | 47713.158% |
| Nanologica AB (publ) | -62.11 Million SEK | -74.758% |
| SynAct Pharma AB | -222.7 Million SEK | 51.254% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -147.505% |
| BioInvent International AB (publ) | -312.7 Million SEK | 65.284% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 35185.145% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 53.131% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -1131.867% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -846.534% |